Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(29%)
Results Posted
67%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
6
86%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
6(85.7%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Active, not recruiting1
unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (85.7%)
Phase 31 (14.3%)

Trials by Status

active_not_recruiting114%
unknown114%
completed343%
recruiting114%
terminated114%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_2

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

NCT06757244
terminatedphase_2

Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

NCT03117972
completedphase_2

Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases

NCT02494973
completedphase_2

Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

NCT02384759
completedphase_2

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem

NCT02352337
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06757244Phase 2

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

Recruiting
NCT03117972Phase 2

Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

Terminated
NCT02494973Phase 2

Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases

Completed
NCT02384759Phase 2

Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

Completed
NCT02352337Phase 2

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem

Completed
NCT03351296Phase 2

Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active Not Recruiting
NCT02502370Phase 3

Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7